EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)Open Access · CC BY-NC-ND 4.0

Preclinical development and a phase 1 trial of IMC001, an EpCAM-targeted CAR-T cell therapy, in patients with advanced gastric cancer

Weijia Fang, Zhengmao Lu, Jingyu Ge, Shuangshuang Zhang, Rui Zheng, Weiwei Yin, Ruidong Hao, Minmin Sun, Tianhang Luo

Molecular Therapy · 2025-11 · 33 (11) · 5516-5529

DOI: 10.1016/j.ymthe.2025.08.014 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift Molecular Therapy, 2025-11. Verfasst von Weijia Fang und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, the First Affiliated Hospital of Zhejiang University, Hangzhou, China. Hauptthemen laut MEDLINE: Stomach Neoplasms, Epithelial Cell Adhesion Molecule, Immunotherapy, Adoptive, Receptors, Chimeric Antigen. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: School of Life Sciences and Biotechnology Division of Life Sciences, Korea University, Changhai Hospital of Shanghai.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Autologous EpCAM-targeted CAR-T cell therapy (IMC001) was developed for advanced gastric cancer (GC). This study evaluated the specificity, efficacy, and safety of IMC001 in preclinical models and a phase 1 dose-escalation/expansion trial in patients who had failed at least two lines of therapy. IMC001 specifically recognized EpCAM and exhibited potent anti-tumor activity in EpCAM+ tumor cells, xenograft models, and patient-derived organoids. From August 2021 to May 2023, 12 advanced GC patients received IMC001. All patients experienced grade 3 or 4 treatment-related adverse events, mainly lymphopenia related to lymphodepletion, with no treatment-related deaths. Five patients experienced cytokine release syndrome (n = 3, grade 3-4) and two patients experienced immune-related hepatitis (n = 1, grade 3 in middle-dose group; n = 1, grade 4 in high-dose group). Partial responses were observed in 33.3% (1/3) of low-dose patients and 40% (2/5) of middle-dose patients, achieving an objective response rate of 30% and a disease control rate of 70%. Median progression-free survival and overall survival were 4.5 and 8.4 months, respectively. One patient underwent conversion surgery at week 27 and remains alive 31.5 months post-infusion. These findings demonstrate an acceptable safety profile and promising efficacy of IMC001 in advanced GC, supporting further clinical development for refractory GC patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Stomach NeoplasmsEpithelial Cell Adhesion MoleculeImmunotherapy, AdoptiveReceptors, Chimeric AntigenHumansMaleFemaleMiddle AgedAgedAnimalsXenograft Model Antitumor AssaysMiceCell Line, TumorAdultTreatment OutcomeNeoplasm Staging

Stichwörter der Autor:innen

CAR-TEpCAMIMC001gastric cancer

Substanzen

Epithelial Cell Adhesion MoleculeEPCAM protein, humanReceptors, Chimeric Antigen

Autor:innen und Institutionen

  • Department of Medical Oncology, the First Affiliated Hospital of Zhejiang University, Hangzhou, China.
  • Department of Gastrointestinal Surgery, Shanghai Changhai Hospital, The Second Military Medical University, Shanghai, China.
  • Suzhou Immunofoco Biotechnology, Suzhou, China; Shanghai Immunofoco Biotech Research, Shanghai, China.
  • Key Laboratory for Biomedical Engineering of the Ministry of Education, College of Biomedical Engineering and Instrument Science, Zhejiang University, Hangzhou, People's Republic of China; Zhejiang Provincial Key Labora…
  • Suzhou Immunofoco Biotechnology, Suzhou, China; Shanghai Immunofoco Biotech Research, Shanghai, China. Electronic address: vincent@immunofoco.com.
  • Suzhou Immunofoco Biotechnology, Suzhou, China; Shanghai Immunofoco Biotech Research, Shanghai, China. Electronic address: minmin.sun@immunofoco.com.

Förderung

  • School of Life Sciences and Biotechnology Division of Life Sciences, Korea University
  • Changhai Hospital of Shanghai

Zitieren

APA

Fang, W., Lu, Z., Ge, J., Zhang, S., Zheng, R., Yin, W., Hao, R., Sun, M., & Luo, T. (2025). Preclinical development and a phase 1 trial of IMC001, an EpCAM-targeted CAR-T cell therapy, in patients with advanced gastric cancer. Molecular Therapy, 33(11), 5516-5529. https://doi.org/10.1016/j.ymthe.2025.08.014

Vancouver

Fang W, Lu Z, Ge J, Zhang S, Zheng R, Yin W, et al. Preclinical development and a phase 1 trial of IMC001, an EpCAM-targeted CAR-T cell therapy, in patients with advanced gastric cancer. Molecular Therapy. 2025;33(11):5516-5529. doi:10.1016/j.ymthe.2025.08.014

BibTeX
@article{Fang2025,
  author = {Fang, Weijia and Lu, Zhengmao and Ge, Jingyu and Zhang, Shuangshuang and Zheng, Rui and Yin, Weiwei and Hao, Ruidong and Sun, Minmin and Luo, Tianhang},
  title = {Preclinical development and a phase 1 trial of IMC001, an EpCAM-targeted CAR-T cell therapy, in patients with advanced gastric cancer},
  journal = {Molecular Therapy},
  year = {2025},
  volume = {33},
  number = {11},
  pages = {5516--5529},
  doi = {10.1016/j.ymthe.2025.08.014}
}
Kostenlos starten →